• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 25, 2016

View Archived Issues

Financings

Hua Medicine Ltd., of Shanghai, closed its series C financing, which combined a U.S. dollar and Chinese renminbi-denominated investment of approximately $50 million. Read More

Other news to note

Baxter International Inc., of Deerfield, Ill., and Baxalta Inc., of Bannockburn, Ill., said Baxter has commenced an offer to exchange up to 12.8 million shares of Baxalta common stock that are currently owned by Baxter, which represents about 1.9 percent of the outstanding common stock of Baxalta, for shares of Baxter common stock that are validly tendered and not validly withdrawn in the exchange offer. Following the completion of the exchange offer, if Baxter disposes of all of the remaining shares of Baxalta common stock held by it in the exchange offer, Baxalta will be wholly independent from Baxter, except that certain agreements between Baxter and Baxalta will remain in place, the companies said. (See BioWorld Today, March 5, 2015.) Read More

Appointments and advancements

Intarcia Therapeutics Inc., of Boston, named Anthony Hurley vice president, global commercial manufacturing and operations, based in Hayward, CA. Read More

In the clinic

Biomarin Pharmaceutical Inc., of San Rafael, Calif., said it enrolled the first patient in a phase I/II trial of BMN 250, its enzyme replacement therapy using a fusion of recombinant human alpha-N-acetyglucosaminidase with a peptide derived from insulin-like growth factor 2, to treat Sanfilippo B syndrome, also known as mucopolysaccharidosis IIIB (MPS IIIB). Read More

Bench Press: BioWorld looks at translational medicine

By sequencing a cohort of aged individuals that were in good health, which they termed "wellderly," scientists from The Scripps Research Institute have identified genetic variants that were associated with healthy aging. Read More

Regulatory front

The FDA made an about-face one day after posting revised briefing documents for Monday's Peripheral and Central Nervous System Drugs (PCNS) Advisory Committee meeting to discuss the new drug application (NDA) for the Duchenne muscular dystrophy (DMD) candidate, eteplirsen, from Sarepta Therapeutics Inc., of Cambridge, Mass. Read More

No more talk: Novartis balks at Colombia price negotiations for Glivec

HONG KONG – Novartis AG pulled out of negotiations with the government of Colombia to determine a price for the leukemia drug Glivec (imatinib). Discussions had been initiated to prevent the issuance of a mandatory license. (See BioWorld Today, April 22, 2016.) Read More

Wait continues as new market teeters on brink of explosion

With U.S. drug prices grabbing headlines and spurring congressional hearings, biosimilars continue to hold out hope for a solution. But hope is not reality. Read More

Former sequencing rivals unite with Astrazeneca in massive genomics effort

LONDON – The two sides in the public-vs.-private race to sequence the human genome have been brought together under the umbrella of an Astrazeneca plc plan to make genomics the foundation of all its future drug discovery and development. Read More

Probody building: Cytomx adds flex with Abbvie deal, gains up to $500M in CD71

CEO Sean McCarthy told BioWorld Today that Cytomx Therapeutics Inc.'s deals will be "increasingly strategic," structured for purposes of "not just bringing cash in the door," and the latest – the firm's third pharma pact – with Abbvie Inc. typifies what he's talking about: "a foundational, pipeline-building" arrangement. Read More

Money bags: Allergan pays $85M up front to buy Topokine under eye fat treatment

Allergan plc is adding experimental ointment for under eye bags to its vanity empire with the acquisition of Topokine Therapeutics Inc. for $85 million up front and undisclosed success-based development and sales milestones. Read More

Dong-A expands global footprint with Tobira in cross-licensing deal

HONG KONG – Dong-A ST. Co. Ltd., an 84-year-old South Korean pharmaceutical company, recently inked two separate licensing agreements with Nasdaq-listed Tobira Therapeutics Inc., as a further sign that Korean firms are reaching deeper into the global biopharma scene through licensing agreements with multinationals. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe